{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '2', 'TABLE OF CONTENTS', '1', 'SYNOPSIS', '9', '2', 'TABLE OF CONTENTS', '17', 'IN-TEXT TABLES', '20', '3', 'LIST OF ABBREVIATIONS', '21', '4', 'INTRODUCTION', '22', '4.1', 'Background on Chronic Leg Wounds', '22', '4.2', 'Prontosan Wound Irrigation Solution and Prontosan Wound Gel', '23', '4.3', 'Clinical Risks/Benefits of Prontosan Solution and Prontosan Gel', '23', '4.4', 'Rationale', '24', '5', 'STUDY OBJECTIVES AND ENDPOINTS', '25', '5.1', 'Study Objectives', '25', '5.1.1', 'Primary Objective', '25', '5.1.2', 'Secondary Objective', '25', '5.1.3', 'Exploratory Objective', '25', '5.2', 'Study Endpoints', '25', '5.2.1', 'Primary Endpoint', '25', '5.2.2', 'Secondary Endpoints', '25', '5.2.3', 'Exploratory Endpoint', '26', '6', 'INVESTIGATIONAL PLAN', '26', '6.1', 'Description of Overall Study Design and Plan', '26', '6.2', 'Discussion of Study Design', '28', '7', 'SELECTION AND WITHDRAWAL OF PATIENTS', '28', '7.1', 'Inclusion Criteria', '28', '7.2', 'Exclusion Criteria', '28', '7.3', 'Withdrawal, Removal, and Replacement of Patients', '30', '7.4', 'Follow-Up for Patient Withdrawal from Study', '30', '8', 'TREATMENTS', '31', '8.1', 'Details of Study Product', '31', '8.2', 'Dosage Schedule', '32', '8.3', 'Accountability and Compliance of Treatment', '32', '8.4', 'Medical History and Prior and Concomitant Medications', '33', '14 November 2018', 'Page 17']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '8.4.1', 'Medical History', '33', '8.4.2', 'Prior and Concomitant Medications', '33', '9', 'STUDY PROCEDURES', '34', '9.1', 'Patient Informed Consent', '37', '9.2', 'Procedures by Study Week', '37', '9.2.1', 'Week 0 (Screening)', '37', '9.2.2', 'Week 1 (Baseline)', '37', '9.2.3', 'Week 2', '38', '9.2.4', 'Weeks 3 and 4', '39', '9.2.5', 'Week 5 (Final Visit: End of Treatment or Early Discontinuation)', '39', '9.2.6', 'Unscheduled Visits', '40', '10', 'CLINICAL OUTCOME ASSESSMENTS', '40', '10.1', 'Wound Quality of Life Questionnaire', '40', '10.2', 'Wound Assessment', '41', '10.3', 'Wound Measurement and Photography', '41', '11', 'SAFETY ASSESSMENTS', '42', '11.1', 'Vital Signs', '42', '11.2', 'Physical Examination', '42', '11.3', 'Laboratory Assessments', '42', '11.4', 'Adverse Events', '43', '11.4.1', 'Adverse Events', '43', '11.4.2', 'Serious Adverse Events and Serious Adverse Device Effects', '44', '11.4.3', 'Serious Adverse Event Reporting', '44', '12', 'STATISTICAL ANALYSIS', '45', '12.1', 'Determination of Sample Size', '45', '12.2', 'Analysis Population', '46', '12.3', 'Disposition', '46', '12.4', 'Demographic and Baseline Characteristics', '46', '12.5', 'Clinical Outcome Analyses', '46', '12.6', 'Safety Analysis', '46', '13', 'STUDY MANAGEMENT', '47', '13.1', 'Study-Specific Materials', '47', '13.2', 'Approval and Consent', '47', '14 November 2018', 'Page 18']\n\n###\n\n", "completion": "END"}